Acta Med. 2025, 68: 77-81
https://doi.org/10.14712/18059694.2025.24
Copeptin (Not Only) in Water and Sodium Disorders
References
1. HJ, Kwon TH. Molecular mechanisms regulating aquaporin-2 in kidney collecting duct. Am J Physiol Renal Physiol. 2016 Dec 1; 311(6): F1318–F1328.
<https://doi.org/10.1152/ajprenal.00485.2016>
<PubMed>
2. RA, Jarrett DB, Verbalis JG, Robinson AG. Vasopressin stimulation of adrenocorticotropin hormone (ACTH) in humans. In vivo bioassay of corticotropin-releasing factor (CRF) which provides evidence for CRF mediation of the diurnal rhythm of ACTH. J Clin Invest. 1988 Mar; 81(3): 766–74.
<https://doi.org/10.1172/JCI113382>
<PubMed>
3. JE, Oksche A, Wollheim CB, Günther G, Rosenthal W, Vischer UM. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest. 2000 Jul; 106(1): 107–16.
<https://doi.org/10.1172/JCI9516>
<PubMed>
4. Leng G, Sabatier N. Measuring Oxytocin and Vasopressin: Bioassays, Immunoassays and Random Numbers. J Neuroendocrinol. 2016 Oct; 28(10): 10.1111/jne.12413.
<https://doi.org/10.1111/jne.12413>
<PubMed>
5. H, Schütz G, Schmale H, Richter D. Nucleotide sequence of cloned cDNA encoding bovine arginine vasopressin-neurophysin II precursor. Nature. 1982 Jan 28; 295(5847): 299–303.
<https://doi.org/10.1038/295299a0>
6. DA. A glycopeptide from the posterior lobe of pig pituitaries. I. Isolation and characterization. Eur J Biochem. 1972 Jul 24; 28(3): 334–9.
<https://doi.org/10.1111/j.1432-1033.1972.tb01918.x>
7. R, Chauvet J, Rouille Y. Dynamic processing of neuropeptides: sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport. J Mol Neurosci. 2002 Jun; 18(3): 223–8.
<https://doi.org/10.1385/JMN:18:3:223>
8. WK, Schnyder I, Koch G, et al. Release and Decay Kinetics of Copeptin vs AVP in Response to Osmotic Alterations in Healthy Volunteers. J Clin Endocrinol Metab. 2018 Feb 1; 103(2): 505–13.
<https://doi.org/10.1210/jc.2017-01891>
9. NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006 Jan; 52(1): 112–9.
<https://doi.org/10.1373/clinchem.2005.060038>
10. N, Grossmann M, Chiang C, Inder WJ. Polyuria-polydipsia syndrome: a diagnostic challenge. Intern Med J. 2018 Mar; 48(3): 244–53.
<https://doi.org/10.1111/imj.13627>
11. JP, Bichet DG. Nephrogenic diabetes insipidus. Annu Rev Physiol. 2001; 63: 607–30.
<https://doi.org/10.1146/annurev.physiol.63.1.607>
12. P, Olsson DS, Ehn O, Ragnarsson O. Diagnostic value of the water deprivation test in the polyuria-polydipsia syndrome. Hormones (Athens). 2017 Oct; 16(4): 414–22.
<https://doi.org/10.14310/horm.2002.1762>
13. W, Refardt J, Chifu I, et al. A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. N Engl J Med. 2018 Aug 2; 379(5): 428–39.
<https://doi.org/10.1056/NEJMoa1803760>
14. Gubbi S, Hannah-Shmouni F, Koch CA, et al. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 30779536.
15. A, Whaley-Connell A, McFarlane S, Sowers JR. Hyponatremia, arginine vasopressin dysregulation, and vasopressin receptor antagonism. Am J Nephrol. 2006; 26(6): 579–89.
<https://doi.org/10.1159/000098028>
16. W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009 Jan; 94(1): 123–9.
<https://doi.org/10.1210/jc.2008-1426>
17. AM, Varaldo E, Zavattaro M, et al. Reassessing the role of copeptin in emergency department admissions for hypotonic hyponatremia. J Clin Endocrinol Metab. 2025 May 3; dgaf266.
18. G, Latini R, Plebani M, et al., FINNRESUSCI Study Group. Copeptin levels are associated with organ dysfunction and death in the intensive care unit after out-of-hospital cardiac arrest. Crit Care. 2015 Mar 31; 19(1): 132.
<https://doi.org/10.1186/s13054-015-0831-y>
<PubMed>
19. JH, Seo YH, Ahn JY. Performance of Copeptin for Early Diagnosis of Acute Myocardial Infarction in an Emergency Department Setting. Ann Lab Med. 2020 Jan; 40(1): 7–14.
<https://doi.org/10.3343/alm.2020.40.1.7>
<PubMed>
20. T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010 May 11; 55(19): 2096–106.
<https://doi.org/10.1016/j.jacc.2010.01.029>
21. L, Gustafsson F. Copeptin as a biomarker in heart failure. Biomark Med. 2014; 8(6): 841–54.
<https://doi.org/10.2217/bmm.14.50>
22. F, Timpka S, Nilsson PM, Melander O, Enhörning S. Copeptin as a predictive marker of incident heart failure. ESC Heart Fail. 2021 Aug; 8(4): 3180–8.
<https://doi.org/10.1002/ehf2.13439>
<PubMed>
23. AI, Tiu C, Badiu C. Copeptin as biomarker for acute ischemic stroke prognosis and revascularization treatment efficacy. Front Neurol. 2024 Dec 13; 15: 1447355.
<https://doi.org/10.3389/fneur.2024.1447355>
<PubMed>
24. K, Velho G, Bouby N. Vasopressin and metabolic disorders: translation from experimental models to clinical use. J Intern Med. 2017 Oct; 282(4): 298–309.
<https://doi.org/10.1111/joim.12649>
25. G, Bouby N, Hadjadj S, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care. 2013 Nov; 36(11): 3639–45.
<https://doi.org/10.2337/dc13-0683>
<PubMed>
